Overall survival with adjuvant pembrolizumab in renal cell carcinoma - the shock of the lightning

Nat Rev Urol. 2024 Oct;21(10):578-579. doi: 10.1038/s41585-024-00896-6.

Authors

Francesco Massari^#^{1

2}, Matteo Rosellini^#^{3

4}, Veronica Mollica³

Affiliations

¹ Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. fmassari79@gmail.com.
² Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. fmassari79@gmail.com.
³ Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
⁴ Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.

^# Contributed equally.

PMID: 38760505
DOI: 10.1038/s41585-024-00896-6

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal, Humanized* / therapeutic use
Antineoplastic Agents, Immunological* / therapeutic use
Carcinoma, Renal Cell* / drug therapy
Carcinoma, Renal Cell* / mortality
Chemotherapy, Adjuvant
Humans
Kidney Neoplasms* / drug therapy
Kidney Neoplasms* / mortality
Survival Rate

Substances

pembrolizumab
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological